News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Cabaletta’s Early Data Shows Potential for Treating Autoimmune Diseases
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
Study highlights growth and impact of Greater Philadelphia’s Booming Cell and Gene Therapy Industry
The Greater Philadelphia Chamber of Commerce published a comprehensive snapshot of the region’s cell and gene therapy sector.
Philadelphia Ranks as 25th Global Startup Ecosystem, According to Startup Genome Report
Startup Genome ranked Philadelphia as 25th within the Global Startup Ecosystem in 2024. The report highlights Penn’s role in supporting the ecosystem through various activities.
$640M in Venture Capital Was Raised in Philly Last Quarter, Signaling that Local VC Investments Are Stabilizing
Philadelphia's venture capital market posted robust results last quarter, with nearly $643 million raised across 100 deals.
Penn Alumni Magazine Recognizes PCI’s Successes Over the Past Decade
PCI and its successful efforts to support Penn's research and innovation over the past decade were highlighted in the Summer issue of the Penn Gazette.
Penn Ranks in Top 15 of US Universities Granted U.S. Patents in 2023
Penn ranked #13 in 2023, compared to #15 in 2022.
PAST WINNERS OF PCI’S AWARDS
Each December, PCI awards Penn faculty, partners and spinout companies with awards for their accomplishments.
Leading Life Sciences Program Highlights Regional Growth
John Swartley, PhD, MBA, provided the keynote address for a public program hosted by the Greater Philadelphia Chamber of Commerce that explored the growth of Greater Philadelphia's ecosystem.
Heirloom Builds Direct Carbon Capture Facility
Heirloom has announced the first phase of a decarbonization project to create two Direct Air Capture (DAC) facilities in North Western Louisiana,
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.